Developing the High-Performance Medical Affairs Functions: Study Excerpt

CHAPEL HILL, N.C., June 3 /PRNewswire/ -- The medical affairs function has always been an important support function at pharmaceutical companies. With major responsibilities to provide customers with medical and scientific information and education, the medical affairs function enhances the efforts of Sales and Marketing to accelerate product and business growth. Furthermore, medical affairs complements the work of Research & Development by maximizing products' total value through continued clinical studies, outcomes research and disease management programs.

The white paper on Roles and Responsibilities: Medical Affairs Growth Strategy highlights findings from a larger research effort undertaken by Best Practices LLC, to benchmark the organization and structure of medical affairs department at top pharmaceutical companies.

Best Practices, LLC's white paper "Developing the High-Performance Medical Affairs Function: Study Excerpt" is now available at http://www.best-in-class.com/cr210.htm

For more information on how Best Practices LLC, can work together to answer your pressing medical affairs business questions, visit www.best-in-class.com or contact Cameron Tew (919) 403-0251, ext. 246, [email protected]

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call (919) 403-0251 or visit www.best-in-class.com .

SOURCE Best Practices, LLC

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.